Cover Image

Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

Chromogranin A (CgA) is a protein found in large dense-core vesicles of neuroendocrine cells and neurons and regulating secretion. A relevance to amyotrophic lateral sclerosis (ALS) was suggested as its overexpression accelerates disease onset in model systems and it interacts with mutant forms of S...

Full description

Saved in:
Bibliographic Details
Main Authors: Verde, Federico (Author) , Steinacker, Petra (Author) , Oeckl, Patrick (Author) , Weishaupt, Jochen H. (Author) , Rosenbohm, Angela (Author) , Silani, Vincenzo (Author) , Ludolph, Albert C. (Author) , Otto, Markus (Author)
Format: Article (Journal)
Language:English
Published: 27 February 2018
In: Neurobiology of aging
Year: 2018, Volume: 67, Pages: 21-22
ISSN:1558-1497
DOI:10.1016/j.neurobiolaging.2018.02.017
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.neurobiolaging.2018.02.017
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0197458018300617
Get full text
Author Notes:Federico Verde, Petra Steinacker, Patrick Oeckl, Jochen H. Weishaupt, Angela Rosenbohm, Vincenzo Silani, Albert C. Ludolph, Markus Otto
Description
Summary:Chromogranin A (CgA) is a protein found in large dense-core vesicles of neuroendocrine cells and neurons and regulating secretion. A relevance to amyotrophic lateral sclerosis (ALS) was suggested as its overexpression accelerates disease onset in model systems and it interacts with mutant forms of SOD1. Recently, increased cerebrospinal fluid (CSF) CgA levels have been reported in ALS patients relative to controls. With the aim of confirming this finding, we measured CgA and phosphorylated neurofilament heavy chain (pNFH), an established ALS biomarker, in the CSF of 32 ALS patients and 32 disease controls. ALS patients had clearly increased pNFH levels (p < 0.0001), while CgA levels were only modestly lower relative to controls (p = 0.0265), with wide value overlap and consequently poor discriminative performance. CgA did not correlate with any disease parameters among ALS patients. Our findings suggest that CgA is not a promising clinical biomarker for ALS.
Item Description:Gesehen am 08.07.2021
Physical Description:Online Resource
ISSN:1558-1497
DOI:10.1016/j.neurobiolaging.2018.02.017

Similar Items